Amyotrophic Lateral Sclerosis (ALS)

MDA Conference Brings Together Researchers, Clinicians, Industry

Moving therapeutic strategies from the laboratory to clinical trials and ultimately to the market as treatments was the theme of the MDA National Scientific Conference held March 13-16, 2011, in Las Vegas.

Some 300 people attended the conference, the first in a planned series of such MDA-sponsored meetings that will emphasize new research and current medical care. The majority of presenters and many of the audience members were current or former MDA research grantees or physicians at MDA-supported clinics.

Faith Keeps Him Singing

The last song Joe Paul Nichols recorded before ALS took his voice was a country gospel standard called “Faith:”

You must have faith
In everything you do
Faith will help you find a way
Faith will see you through

Faith can move mountains
And change the tide at sea
You can follow this guiding light
Wherever you may be

Reactivated Virus May Contribute to ALS

New research suggests that the DNA of a normally dormant virus may be playing a role in causing amyotrophic lateral sclerosis (ALS).

If the findings are confirmed, they could ultimately have implications for treatment of the disease.

About the HERV-K virus

ALS Research Briefs

Loss of TDP43's normal function could be ALS contributor

MDA Awards $2 Million to ALS TDI

MDA has awarded $2 million to the ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., to help scientists complete the preclinical testing of four promising new compounds in ALS TDI's drug development pipeline. 

The grant, made through MDA's Augie's Quest ALS fundraising initiative, raises MDA's total grant contributions to ALS TDI to more than $23.4 million since 2007.

About the new funding

ALS TDI plans to test the four new compounds in the SOD1 ALS research mouse model.

ALS Therapy Development Institute: Looking Ahead to 2011

New space for research, new mouse models of ALS and new technology to screen therapeutic agents all will play a role in 2011 at the ALS Therapy Development Institute (ALS TDI), said Steve Perrin, ALS TDI chief scientific officer and CEO, in the biotech's monthly webinar in January.

Accelerate ALS research

Perrin listed a number of specific milestones the Institute hopes to reach in 2011.

Eight New Grants Bolster MDA's Battle Against ALS

MDA has awarded eight new grants totaling nearly $2.5 million to fund research projects focused on uncovering the causes of, and developing therapies for, ALS. The effective start date for the grants was Feb. 1, 2011.

MDA Awards $13.5 Million in Research Grants

The Muscular Dystrophy Association has awarded 44 grants totaling $13.5 million to support research efforts aimed at advancing understanding of disease processes and uncovering new strategies for treatments and cures of muscular dystrophy and the more than 40 other diseases in the Association’s program.

The new grants were reviewed by MDA’s Scientific and Medical Advisory Committees, and approved by MDA’s Board of Directors at its December meeting.

Isis Hosts Webinar for SOD1-Rx Trial

Isis Pharmaceuticals hosted an interactive webinar Wednesday, March 2, 2011, at 12 noon Eastern Standard Time, to help prospective participants understand its MDA-supported, phase 1 study of ISIS-SOD1-Rx for people with familial amyotrophic lateral sclerosis (ALS) due to mutations in the SOD1 gene.

For those unable to participate during the live webinar, a replay will be available for a limited time on the Isis website.

Clinical Trial Info: Ceftriaxone in ALS

Researchers conducting a clinical trial of the antibiotic ceftriaxone in amyotrophic lateral sclerosis (ALS) currently are recruiting participants at 57 locations across the United States and Canada.

Pages